(Q50052540)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Sudipto Mukherjee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Jay P Ciezki

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

May Abdel-Wahab

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Ramon V Tiu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Edward Copelan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Anjali A Advani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Yogen Saunthararajah

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Katarina Paulic

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Sean Hobson

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Jaroslaw P Maciejewski

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Brian J Bolwell

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Matt Kalaycio

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Robert Dreicer

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Eric A Klein

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Mikkael A Sekeres

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

27 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

djt462

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577815%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Second primary cancers following cancers of the kidney and prostate in New South Wales (Australia), 1972-91.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Risk of multiple primary cancers in prostate cancer patients in the Detroit metropolitan area: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Cancer incidence after localized therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Increased risk of rectal cancer after prostate radiation: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Novel trafficking routes for hematopoietic stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Leukemia following Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Second acute leukemia and other malignancies following treatment for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Acute leukaemia in patients treated for Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Second neoplasms in patients with Hodgkin's disease following combined modality therapy--the Yale experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Total body irradiation for stage II-IV non-Hodgkin's lymphoma: ten-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462

Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT462